Please ensure Javascript is enabled for purposes of website accessibility

Biogen Sinks Despite Raft of Analyst Upgrades

By Eric Volkman - Jun 8, 2021 at 6:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Aduhelm effect seems to be quickly wearing off the stock.

One day after flying sky high, Biogen (BIIB 1.27%) stock quickly obeyed gravity by falling marginally on Tuesday.

Interestingly, this came on a day when several analysts raised their price targets and/or recommendations on the stock. This was entirely expected, after the Food and Drug Administration (FDA) approved the company's aducanumab on Monday.

Patient, wearing a mask, conferring with a doctor, similarly masked.

Image source: Getty Images.

The drug, which was developed with partner Eisai and will be marketed under the brand name Aduhelm, is a controversial treatment for Alzheimer's disease. It is the first Alzheimer's drug to receive an FDA nod since 2003.

Among the Biogen raisers was Stifel's Paul Matteis, who dramatically lifted his price target on the stock by $100 to $446 per share while maintaining his buy rating. In his view, with Aduhelm on the market "our peak revenue opportunity in the U.S. is now doubled at [approximately] $9 billion in 2030."

Other prognosticators becoming notably more bullish on Biogen Tuesday included William Blair's Matt Phipps; he cranked his recommendation one notch higher, to outperform (read: buy) from the previous market perform (neutral). Michael Yee of Jefferies tagged the stock with the Street High designation, and a new price target of $500 (up from the former $450).

But the controversy over Aduhelm isn't likely to melt away anytime soon. There are questions about its efficacy and concerns about its high price tag. On Tuesday, Sen. Ron Wyden, Democrat of Oregon, wrote in a tweet that it was "unconscionable to ask seniors and taxpayers to pay $56,000 a year for a drug that has yet to be proven effective."


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Jefferies Financial Group Inc. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$220.99 (1.27%) $2.77
Jefferies Financial Group Inc. Stock Quote
Jefferies Financial Group Inc.
$34.86 (1.87%) $0.64
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
$46.02 (-0.41%) $0.19
Stifel Financial Corp. Stock Quote
Stifel Financial Corp.
$64.55 (1.56%) $0.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.